Skip to main
LONA

LeonaBio Inc (LONA) Stock Forecast & Price Target

LeonaBio Inc (LONA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LeonaBio is a clinical-stage biopharmaceutical company that operates as a single operating segment, developing and commercializing novel therapeutics, including lasofoxifene and ATH-1105, with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). Its top-tier drug candidates have demonstrated strong clinical data, with results showing statistically significant improvement in PFS and potential to become one of the next endocrine therapy backbones in the large ER+/HER2- mBC market. The company is well-positioned to compete in this market with its pipeline of small-molecule drugs targeting the HGF/MET pathway. With additional future shots at goal in other mutational subsets and a strong financial position, LeonaBio has minimal risk and a high potential for growth in the oncology space.

Bears say

LeonaBio is a clinical-stage biopharmaceutical company operating in a highly competitive market. While their key drug candidates have shown promising results in clinical trials, the company's current financials and resources may not be enough to effectively commercialize and compete against established players. Additionally, the company's dependence on a few drug candidates and lack of diversification in their pipeline pose significant risks to its long-term success.

LeonaBio Inc (LONA) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeonaBio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeonaBio Inc (LONA) Forecast

Analysts have given LeonaBio Inc (LONA) a Buy based on their latest research and market trends.

According to 3 analysts, LeonaBio Inc (LONA) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeonaBio Inc (LONA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.